Myovant Sciences Ltd. Quarterly Share-based Payment Arrangement, Expense in USD from Q1 2016 to Q4 2022

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Myovant Sciences Ltd. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q1 2016 to Q4 2022.
  • Myovant Sciences Ltd. Share-based Payment Arrangement, Expense for the quarter ending December 31, 2022 was $11M, a 55.8% increase year-over-year.
  • Myovant Sciences Ltd. Share-based Payment Arrangement, Expense for the twelve months ending December 31, 2022 was $41.5M, a 32.9% decline year-over-year.
  • Myovant Sciences Ltd. annual Share-based Payment Arrangement, Expense for 2021 was $38.9M, a 27.5% decline from 2020.
  • Myovant Sciences Ltd. annual Share-based Payment Arrangement, Expense for 2020 was $53.7M, a 33.4% increase from 2019.
  • Myovant Sciences Ltd. annual Share-based Payment Arrangement, Expense for 2019 was $40.3M, a 115% increase from 2018.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q4 2022 $41.5M $11M +$3.93M +55.8% Oct 1, 2022 Dec 31, 2022 10-Q 2023-01-26
Q3 2022 $37.5M $11.7M +$15K +0.13% Jul 1, 2022 Sep 30, 2022 10-Q 2022-10-26
Q2 2022 $37.5M $9.71M -$1.41M -12.7% Apr 1, 2022 Jun 30, 2022 10-Q 2022-07-27
Q1 2022 $38.9M $9.06M -$22.9M -71.6% Jan 1, 2022 Mar 31, 2022 10-K 2022-05-11
Q4 2021 $61.8M $7.05M +$37K +0.53% Oct 1, 2021 Dec 31, 2021 10-Q 2023-01-26
Q3 2021 $61.8M $11.7M +$4.78M +69% Jul 1, 2021 Sep 30, 2021 10-Q 2022-10-26
Q2 2021 $57M $11.1M +$3.3M +42.3% Apr 1, 2021 Jun 30, 2021 10-Q 2022-07-27
Q1 2021 $53.7M $31.9M +$25.9M +426% Jan 1, 2021 Mar 31, 2021 10-K 2022-05-11
Q4 2020 $27.8M $7.01M -$12.8M -64.6% Oct 1, 2020 Dec 31, 2020 10-Q 2022-01-26
Q3 2020 $40.6M $6.92M -$1.01M -12.7% Jul 1, 2020 Sep 30, 2020 10-Q 2021-10-26
Q2 2020 $41.6M $7.81M +$1.36M +21.1% Apr 1, 2020 Jun 30, 2020 10-Q 2021-07-28
Q1 2020 $40.3M $6.07M +$1.14M +23.1% Jan 1, 2020 Mar 31, 2020 10-K 2022-05-11
Q4 2019 $39.1M $19.8M +$15M +313% Oct 1, 2019 Dec 31, 2019 10-Q 2021-02-11
Q3 2019 $24.1M $7.93M +$3.21M +67.9% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-12
Q2 2019 $20.9M $6.45M +$2.21M +52% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-11
Q1 2019 $18.7M $4.93M +$1.59M +47.7% Jan 1, 2019 Mar 31, 2019 10-K 2021-05-11
Q4 2018 $17.1M $4.79M +$1.5M +45.6% Oct 1, 2018 Dec 31, 2018 10-Q 2020-02-10
Q3 2018 $15.6M $4.73M +$1.98M +71.9% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-12
Q2 2018 $13.6M $4.24M +$2.04M +92.8% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-06
Q1 2018 $11.6M $3.34M Jan 1, 2018 Mar 31, 2018 10-K 2020-05-18
Q4 2017 $3.29M Oct 1, 2017 Dec 31, 2017 10-Q 2019-02-07
Q3 2017 $2.75M Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-08
Q2 2017 $2.2M Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-07
Q1 2016 $987K Feb 3, 2016 Mar 31, 2016 10-K 2018-06-07
* An asterisk sign (*) next to the value indicates that the value is likely invalid.